These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2702092)

  • 1. Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.
    Nakamura M; Weil WB; Kaufman DB
    Pediatr Nephrol; 1989 Jan; 3(1):80-2. PubMed ID: 2702092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
    Boelaert JR; van Roost GF; Vergauwe PL; Verbanck JJ; de Vroey C; Segaert MF
    Clin Nephrol; 1988 May; 29(5):261-6. PubMed ID: 3293856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritonitis due to Rhizopus in a patient undergoing continuous ambulatory peritoneal dialysis.
    Branton MH; Johnson SC; Brooke JD; Hasbargen JA
    Rev Infect Dis; 1991; 13(1):19-21. PubMed ID: 2017628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine.
    Windus DW; Stokes TJ; Julian BA; Fenves AZ
    Ann Intern Med; 1987 Nov; 107(5):678-80. PubMed ID: 3662280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal mucormycosis in a patient receiving continuous ambulatory peritoneal dialysis.
    Polo JR; Luño J; Menarguez C; Gallego E; Robles R; Hernandez P
    Am J Kidney Dis; 1989 Mar; 13(3):237-9. PubMed ID: 2919604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.
    Boelaert JR; de Locht M; Van Cutsem J; Kerrels V; Cantinieaux B; Verdonck A; Van Landuyt HW; Schneider YJ
    J Clin Invest; 1993 May; 91(5):1979-86. PubMed ID: 8486769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine].
    Arizono K; Fukui H; Miura H; Hayano K; Otsuka Y; Tajiri M
    Nihon Jinzo Gakkai Shi; 1989 Jan; 31(1):99-103. PubMed ID: 2747004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry.
    Boelaert JR; Fenves AZ; Coburn JW
    Am J Kidney Dis; 1991 Dec; 18(6):660-7. PubMed ID: 1962650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of peritonitis by C. bertholletiae in a chronic kidney failure patient on continuous ambulatory peritoneal dialysis after kidney rejection.
    Bhutada K; Borkar SS; Mendiratta DK; Shende VR
    Singapore Med J; 2012 May; 53(5):e106-9. PubMed ID: 22584986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine.
    Kaneko T; Abe F; Ito M; Hotchi M; Yamada K; Okada Y
    Acta Pathol Jpn; 1991 Jul; 41(7):561-6. PubMed ID: 1755321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal mucormycosis in a patient on CAPD.
    Nayak S; Satish R; Gokulnath ; Savio J; Rajalakshmi T
    Perit Dial Int; 2007; 27(2):216-7. PubMed ID: 17299165
    [No Abstract]   [Full Text] [Related]  

  • 12. Mucormycosis--a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload?
    Goodill JJ; Abuelo JG
    N Engl J Med; 1987 Jul; 317(1):54. PubMed ID: 3587314
    [No Abstract]   [Full Text] [Related]  

  • 13. [Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine].
    Ponz E; Campistol JM; Ribalta T; Montoliú J; Ramírez J; Almirall J; Revert L
    Rev Clin Esp; 1991 Feb; 188(2):85-7. PubMed ID: 2041907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus.
    de Locht M; Boelaert JR; Schneider YJ
    Biochem Pharmacol; 1994 May; 47(10):1843-50. PubMed ID: 8204101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonococcal peritonitis in a patient treated with continuous ambulatory peritoneal dialysis (CAPD).
    Wolfson AB; Nachamkin I; Singer I; Moffitt CM; Buchan AM
    Am J Kidney Dis; 1985 Oct; 6(4):257-60. PubMed ID: 4050785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).
    Van Cutsem J; Boelaert JR
    Kidney Int; 1989 Dec; 36(6):1061-8. PubMed ID: 2601256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhodotorula rubra peritonitis in patients undergoing continuous ambulatory peritoneal dialysis.
    Eisenberg ES; Alpert BE; Weiss RA; Mittman N; Soeiro R
    Am J Med; 1983 Aug; 75(2):349-52. PubMed ID: 6881189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with deferoxamine: a real risk factor for mucormycosis?
    Vlasveld LT; van Asbeck BS
    Nephron; 1991; 57(4):487-8. PubMed ID: 2046837
    [No Abstract]   [Full Text] [Related]  

  • 19. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
    Boelaert JR; Van Cutsem J; de Locht M; Schneider YJ; Crichton RR
    Kidney Int; 1994 Mar; 45(3):667-71. PubMed ID: 8196268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.